QNRX news

Quoin Pharmaceuticals reported the successful compassionate-use treatment of a pediatric patient using QRX003, which resulted in dramatic skin improvements and significant symptom relief, supporting potential market relevance for its rare disease drug development.

Quoin Pharmaceutical’s QRX003 has been granted Orphan Drug Designation in Europe for the treatment of Peeling Skin Syndrome, providing market exclusivity and supporting the initiation of a clinical trial before year end.

Quoin Pharmaceuticals announced the FDA granted Fast Track designation to QRX003 for Peeling Skin Syndrome, a disease with no approved treatment. This is the second indication for which the serine protease inhibitor has received the designation.

Japan's MHLW granted orphan drug designation for QRX003 in Netherton Syndrome, providing up to 10 years of market exclusivity and regulatory incentives. This adds to prior FDA and EMA designations, supporting Quoin's strategy to self-commercialize in Japan as a core market.